Further $7m to back cardiac arrhythmia co
This article was originally published in Clinica
Executive Summary
Rhythmia Medical has closed a $7m series B financing led by Norwich Ventures. Other participants in the round include unnamed "medical device industry leaders" as well as previous investors in Woburn, Massachusetts-based startup. The proceeds will be used to accelerate its R&D activities and expand its workforce. Rhythmia is developing a minimally-invasive medical device for treating cardiac arrhythmia. It expects to initiate animal studies within 18-24 months.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.